亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

207-OR: Myostatin Inhibition Synergizes with GLP-1R Agonism to Accelerate Weight Loss in Male, Obese Nonhuman Primates

肌生成抑制素 内科学 减肥 内分泌学 封锁 脂肪团 医学 瘦体质量 脂肪组织 2型糖尿病 骨骼肌 肥胖 受体 体重 糖尿病
作者
Jason Mastaitis,Daniel R. Gomez,Valerie Le Rouzic,Michael J. Stec,NAVEEN KHAN,Erqian Na,Toya McWilliams,Soo Min,MARK SLEEMAN
出处
期刊:Diabetes [American Diabetes Association]
卷期号:72 (Supplement_1) 被引量:9
标识
DOI:10.2337/db23-207-or
摘要

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become standard-of-care for the pharmacological treatment of obesity by inducing clinically meaningful weight loss through a reduction in appetite. While these agents potently reduce fat mass, the caloric restriction also reduces skeletal muscle mass. Strategies to preserve skeletal muscle in the presence of caloric restriction are needed to improve weight loss quality in obese patents. Trevogrumab (∝-MSTN) and garetosmab (∝-ActA) are fully human monoclonal antibodies that potently inhibit two mediators of skeletal muscle atrophy: myostatin (MSTN) and activin A (ActA). We first tested the effects of ∝-MSTN, ∝-ActA and GLP-1RA (Semaglutide [Sema]) on body composition of diet-induced obese mice either alone or in combination. Sema (-29.8%) and ∝-MSTN/∝-ActA (-23.4%) produced significant reduction in fat mass after 4 weeks of treatment vs baseline. Adding MTSN and ActA blockade to Sema produced an additive effect on fat mass (-54.2%). This combination also increased lean mass by 9.8% vs a 1.9% loss with Sema alone. To test this in primates, we performed a 20-week study with the combined administration of either Sema + ∝-MSTN or Sema + ∝-MSTN and ∝-ActA in obese male cynomolgus monkeys. The combination of ∝-MSTN + Sema was sufficient to cause an additive effect on fat mass -43.9% vs -25.1% for Sema alone. The addition of ∝-ActA to the combination produced a similar reduction in fat (-49.6%). The Sema control group also lost -2.5% lean mass after 20 weeks; despite the significant reduction in fat mass, the addition of ∝-MSTN to Sema slightly increased lean mass over the same period (0.5%); the addition of ∝-ActA increased lean mass even further (6.2%). These data suggest the blockade of MSTN and ActA to GLP-1RA treatment could greatly improve the quality of weight loss with this class of anti-obesity agents. Disclosure J.Mastaitis: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. D.Gomez: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. V.Le rouzic: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. M.Stec: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. N.Khan: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. E.Na: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. T.Mcwilliams: None. S.Min: Employee; Regeneron Pharmaceuticals Inc., Stock/Shareholder; Regeneron Pharmaceuticals Inc. M.Sleeman: Employee; Regeneron Pharmaceuticals Inc. Funding Regeneron Pharmaceuticals Inc.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
雨晨完成签到,获得积分20
刚刚
1秒前
1秒前
sleepy发布了新的文献求助10
5秒前
九离完成签到,获得积分10
6秒前
labor完成签到,获得积分10
6秒前
7秒前
庾傀斗发布了新的文献求助10
8秒前
上官若男的应助被美满惜雪采纳,获得10
11秒前
Diamond完成签到 ,获得积分10
12秒前
庾傀斗发布了新的文献求助10
13秒前
jj发布了新的文献求助10
13秒前
整齐诺言完成签到,获得积分10
14秒前
15秒前
Bin_Liu完成签到,获得积分20
16秒前
滴滴答答完成签到 ,获得积分10
16秒前
17秒前
庾傀斗发布了新的文献求助10
18秒前
小羊完成签到,获得积分0
18秒前
19秒前
jj发布了新的文献求助10
20秒前
乐乐的应助被Jazz5688采纳,获得30
20秒前
聪慧哲瀚完成签到,获得积分10
21秒前
GingerF给芒果的求助进行了留言
23秒前
美满惜雪发布了新的文献求助10
24秒前
Nole的应助被露稚采纳,获得10
25秒前
笑点低的踏歌完成签到,获得积分20
27秒前
烟花的应助被飘逸小之采纳,获得10
29秒前
bkagyin的应助被美满惜雪采纳,获得10
30秒前
33秒前
搜集达人的应助被科研通管家采纳,获得10
37秒前
顾矜的应助被科研通管家采纳,获得10
37秒前
Hello的应助被科研通管家采纳,获得10
37秒前
情怀的应助被科研通管家采纳,获得10
37秒前
在水一方的应助被科研通管家采纳,获得10
37秒前
syvshc的应助被千仞采纳,获得10
37秒前
田様的应助被科研通管家采纳,获得10
38秒前
梦梦的应助被科研通管家采纳,获得10
38秒前
Crssss的应助被科研通管家采纳,获得20
38秒前
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184945
求助须知:如何正确求助?哪些是违规求助? 9573899
关于积分的说明 21833591
捐赠科研通 7782403
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161